<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3741139</article-id><article-id pub-id-type="pmid">23951239</article-id><article-id pub-id-type="publisher-id">PONE-D-13-17464</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0071755</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome Expression Analysis</subject></subj-group></subj-group><subj-group><subject>Molecular Genetics</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group><subj-group><subject>Microarrays</subject></subj-group></subj-group><subj-group><subject>Genetics</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group><subj-group><subject>Genomics</subject><subj-group><subject>Genome Expression Analysis</subject></subj-group></subj-group><subj-group><subject>Molecular Cell Biology</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Colon</subject></subj-group></subj-group><subj-group><subject>Oncology</subject><subj-group><subject>Basic Cancer Research</subject><subj-group><subject>Tumor Physiology</subject></subj-group></subj-group><subj-group><subject>Cancer Risk Factors</subject><subj-group><subject>Genetic Causes of Cancer</subject><subject>Predisposing Conditions and Syndromes</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Distinct Gene Expression Signatures in Lynch Syndrome and Familial Colorectal Cancer Type X </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Gene Expression in Lynch Syndrome and FCCTX</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Dominguez-Valentin</surname><given-names>Mev</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Therkildsen</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Veerla</surname><given-names>Srinivas</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jönsson</surname><given-names>Mats</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bernstein</surname><given-names>Inge</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Borg</surname><given-names>Åke</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nilbert</surname><given-names>Mef</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Oncology, Institute of Clinical Sciences, Lund University, Lund, Sweden</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>The Danish HNPCC Register, Clinical Research Centre and Department of Gastroenterology, Copenhagen University Hospital, Hvidovre, Denmark</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>de Mello</surname><given-names>Ramon Andrade</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Faculty of Medicine, University of Porto, Portugal</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>mev_dv@yahoo.com</email></corresp><fn fn-type="COI-statement"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: MDV CT MN SV MJ AB IB. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: MDV MJ. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: MDV SV. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: MDV CT SV MJ IB AB MN. </plain></SENT>
<SENT sid="6" pm="."><plain>Wrote the paper: MDV CT MN. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>12</day><month>8</month><year>2013</year></pub-date><volume>8</volume><issue>8</issue><elocation-id>e71755</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 Dominguez-Valentin et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Dominguez-Valentin et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title><text><SENT sid="7" pm="."><plain>Introduction </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="8" pm="."><plain>Heredity is estimated to cause at least 20% of colorectal cancer. </plain></SENT>
<SENT sid="9" pm="."><plain>The hereditary nonpolyposis colorectal cancer subset is divided into Lynch syndrome and familial colorectal cancer type X (FCCTX) based on presence of mismatch repair (MMR) gene defects. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="10" pm="."><plain>Purpose </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>We addressed the gene expression signatures in colorectal cancer linked to Lynch syndrome and FCCTX with the aim to identify candidate genes and to map signaling pathways relevant in hereditary colorectal carcinogenesis. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="12" pm="."><plain>Experimental design </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>The 18 k whole-genome c-DNA-mediated annealing, selection, extension, and ligation (WG-DASL) assay was applied to 123 colorectal cancers, including 39 Lynch syndrome tumors and 37 FCCTX tumors. </plain></SENT>
<SENT sid="14" pm="."><plain>Target genes were technically validated using real-time quantitative RT-PCR (qRT-PCR) and the expression signature was validated in independent datasets. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="15" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="16" pm="."><plain>Colorectal cancers linked to Lynch syndrome and FCCTX showed distinct gene expression profiles, which by significance analysis of microarrays (SAM) differed by 2188 genes. </plain></SENT>
<SENT sid="17" pm="."><plain>Functional pathways involved were related to G-protein coupled receptor signaling, oxidative phosphorylation, and cell cycle function and mitosis. </plain></SENT>
<SENT sid="18" pm="."><plain>qRT-PCR verified altered expression of the selected genes NDUFA9, AXIN2, MYC, DNA2 and H2AFZ. </plain></SENT>
<SENT sid="19" pm="."><plain>Application of the 2188-gene signature to independent datasets showed strong correlation to MMR status. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="20" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="21" pm="."><plain>Distinct genetic profiles and deregulation of different canonical pathways apply to Lynch syndrome and FCCTX and key targets herein may be relevant to pursue for refined diagnostic and therapeutic strategies in hereditary colorectal cancer. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><funding-statement>The Danish and the Swedish Cancer Funds, from the Swedish Research Council, the Lundbeck foundation, the Nilsson Cancer Fund, the Kamprad Cancer Fund and the Hvidovre University Hospital, Denmark. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="7"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="22" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="23" pm="."><plain>Heredity is a major risk factor for colorectal cancer. </plain></SENT>
<SENT sid="24" pm="."><plain>Identification of individuals and families at increased risk allows for targeted surveillance, which has been shown to reduce morbidity and mortality from colorectal cancer [1], [2]. </plain></SENT>
<SENT sid="25" pm="."><plain>Hereditary nonpolyposis colorectal cancer (HNPCC) accounts for 3–6% of colorectal cancer. </plain></SENT>
<SENT sid="26" pm="."><plain>The syndrome is clinically classified according to the Amsterdam criteria, which require at least three HNPCC-associated cancers, two affected first-degree relatives and at least one individual diagnosed before age 50 [3], [4]. </plain></SENT>
<SENT sid="27" pm="."><plain>Between one-third and half of the families that fulfill the Amsterdam criteria carry germline mismatch repair (MMR) gene mutations in MLH1, MSH2, MSH6 or PMS2 and are referred to as having Lynch syndrome [5]–[7]. </plain></SENT>
<SENT sid="28" pm="."><plain>The remaining families with a yet unidentified genetic background show a predominance of colorectal cancer, frequent synchronous and metachronous adenomatous polyps and few extracolonic tumors and are referred to as familial colorectal cancer type X (FCCTX) [8], [9]. </plain></SENT>
<SENT sid="29" pm="."><plain>Compared to Lynch syndrome, colorectal cancers linked to FCCTX develop later, predominantly occur in the distal colon and less often show the distinctive morphological features tumor-infiltrating lymphocytes, poor differentiation and mucin production characteristic of Lynch syndrome tumors [8], [10], [11]. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>Data on the genetic features and tumorigenic pathways of FCCTX are scarce though genomic studies have demonstrated mean 6–8 copy number alterations with recurrent gains of 7p, 7q, 8q, 13q, 20p and 20q and losses of 17p, 18p and 18q [9], [12], [13]. </plain></SENT>
<SENT sid="31" pm="."><plain>Two studies have addressed gene expression profiles and mutation patterns in FCCTX tumors and have described similarities between FCCTX and sporadic MMR stable tumors [14], [15]. </plain></SENT>
<SENT sid="32" pm="."><plain>In sporadic colorectal cancer, MMR defective tumors show distinct gene expression profiles with up-regulation of immunomodulatory genes, such as chaperones, cytokines and cytotoxic mediators, heat shock genes, major histocompatibility complex genes and apoptosis-related genes [16]–[18]. </plain></SENT>
<SENT sid="33" pm="."><plain>We applied global gene expression profiling in order to delineate candidate genes and differential involvement of pathways within the HNPCC subset of hereditary colorectal cancer with comparison between colorectal cancer linked to Lynch syndrome and FCCTX. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s2"><title><text><SENT sid="34" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="35" pm="."><plain>Ethics Statement </plain></SENT>
</text></title><p><text><SENT sid="36" pm="."><plain>The project was ethically reviewed in Copenhagen, where a waiver for collection of tissues and clinical data was granted. </plain></SENT>
<SENT sid="37" pm="."><plain>All patients provided an informed consent for inclusion into the Danish HNPCC register during genetic counselling sessions. </plain></SENT>
<SENT sid="38" pm="."><plain>Ethical approval for the study was granted from the Scientific and Ethical Committee at The Capital Region of Copenhagen, Denmark (H-D-2007–0032). </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="39" pm="."><plain>Sample Selection and RNA Extraction </plain></SENT>
</text></title><p><text><SENT sid="40" pm="."><plain>The national Danish HNPCC register was used to identify colorectal cancers from individuals with Lynch syndrome and FCCTX. </plain></SENT>
<SENT sid="41" pm="."><plain>Lynch syndrome was defined as families/individuals with disease-predisposing germline MMR gene mutations (n = 16 in MLH1, n = 13 in MSH2 and n = 10 in MSH6). </plain></SENT>
<SENT sid="42" pm="."><plain>Immunohistochemical MMR protein staining and microsatellite instability (MSI) analysis were performed as previously described [11], [13]. </plain></SENT>
<SENT sid="43" pm="."><plain>FCCTX tumors were defined as tumors that developed in families fulfilling the Amsterdam criteria, but showed no disease-predisposing MMR gene mutations and had retained MMR function. </plain></SENT>
<SENT sid="44" pm="."><plain>Sporadic colorectal cancers were selected to represent MMR deficient and MMR proficient tumors from individuals without family history of cancer. </plain></SENT>
<SENT sid="45" pm="."><plain>Clinical data are summarized in Table 1. </plain></SENT>
<SENT sid="46" pm="."><plain>Compared to Lynch syndrome tumors, FCCTX tumors were more often located in the left side of the colon (p&lt;0.00001, Fisheŕs exact test) and showed high or moderate differentiation (p&lt;0.00001, Fisheŕs exact test). </plain></SENT>
<SENT sid="47" pm="."><plain>Lynch syndrome and FCCTX did not differ as regards age at onset (mean 53 years versus 58 years) or tumor stage. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0071755-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071755.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="48" pm="."><plain>Clinical characteristics of the colorectal cancer subsets. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0071755-t001-1" xlink:href="pone.0071755.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain>Characteristics </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>Lynch syndrome </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>FCCTX </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>Sporadic MMR deficient </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>Sporadic MMR proficient </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>Number of tumors profiled </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain>39 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>37 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>26 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>21 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>Mean (range) age at onset </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>53 (25–86) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>58 (33–88) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>74 (62–86) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>69 (51–83) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>Sex (% female) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>54 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>38 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>54 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>57 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>Tumor location, proximal/distal (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>77/23 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>5/95 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>81/19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>52/48 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>Differentiation, high-moderate/low (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>67/33 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>92/8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>46/54 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>86/14 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>Tumor stage distribution (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>I:13, II:51, III:36 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>I:8, II:43, III:49 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>I:4, II:73, III:15 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>I:0, II:43, III:57 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><p><text><SENT sid="84" pm="."><plain>Non-necrotic tumor areas were macro-dissected and RNA extraction was performed from three 5-µm sections of paraffin-embedded tumor tissue [11], [13] using the High Pure RNA Paraffin Kit (Roche, Castle Hill, Australia) according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="85" pm="."><plain>RNA concentration was determined using a NanoDrop Spectrophotometer (NanoDrop Technologies, Wilmington, DE) and samples yielding sufficient RNA (200 ng) with 260/280 ratios &gt;1.8 were selected. </plain></SENT>
</text></p></sec><sec id="s2c"><title><text><SENT sid="86" pm="."><plain>Gene Expression Profiling </plain></SENT>
</text></title><p><text><SENT sid="87" pm="."><plain>Gene expression analyses were performed at the SCIBLU Genomics Centre, Lund University, Sweden. </plain></SENT>
<SENT sid="88" pm="."><plain>The Illumina Bead-array (HumanWG-6 v4 Expression Beadchip, Illumina) system was used according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="89" pm="."><plain>Briefly, total RNA was converted to cDNA using biotinylated oligo-dT18 and random nonamer primers. </plain></SENT>
<SENT sid="90" pm="."><plain>Two assay-specific oligonucleotides were designed to interrogate a single contiguous 50 nt sequence on each cDNA. </plain></SENT>
<SENT sid="91" pm="."><plain>Each of these oligonucleotides consisted of two parts: an upstream-specific oligonucleotide (USO) containing a 3′ gene-specific sequence and a 5′ universal PCR primer sequence (P1), while the downstream-specific oligonucleotide (DSO) contained a 5′ gene-specific sequence and a different 3′ universal PCR primer sequence (P2). </plain></SENT>
<SENT sid="92" pm="."><plain>Using this approach, a total of 24,526 oligonucleotide pairs (probes) were designed and pooled, which together constituted the whole genome (WG) DASL assay pool (DAP), corresponding to 18,626 unique genes, based on well-annotated content derived from the National Center for Biotechnology Information (NCBI) Reference Sequence Database (Build 36.2, Release 22). </plain></SENT>
<SENT sid="93" pm="."><plain>The DAP was then annealed to the targeted cDNAs, followed by enzymatic extension and ligation steps, as previously described [19]. </plain></SENT>
<SENT sid="94" pm="."><plain>Ligated products were PCR-amplified and labeled with a universal Cy3-coupled primer after which single-stranded labeled products were precipitated and hybridized to WG gene expression BeadChips as previously described [20]. </plain></SENT>
<SENT sid="95" pm="."><plain>BeadChips were then scanned on a BeadArray™ Reader using BeadScan software (v4.2), during which fluorescence intensities were read and images extracted. </plain></SENT>
</text></p></sec><sec id="s2d"><title><text><SENT sid="96" pm="."><plain>Data Analysis </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>Expression data were uploaded and processed in the GenomeStudio software (Illumina, San Diego, CA). </plain></SENT>
<SENT sid="98" pm="."><plain>Data were normalized using background correction, cubic spline method [21] and plate scaling. </plain></SENT>
<SENT sid="99" pm="."><plain>RefSeq features with a detection P value of ≤0.01 in at least 80% of the samples were used, leaving 9,218 features for further analysis. </plain></SENT>
<SENT sid="100" pm="."><plain>The data were uploaded into MeV v4 [22] where they were log2 transformed and median-centered across assays. </plain></SENT>
<SENT sid="101" pm="."><plain>Unsupervised clustering was performed on the total set of CRC samples using average linkage clustering with a Pearson correlation as similarity metric. </plain></SENT>
<SENT sid="102" pm="."><plain>Significance analysis of microarrays (SAM) [23] was used to identify significantly differentially expressed genes with a false-discovery rate (FDR) ≤5% [24]. </plain></SENT>
<SENT sid="103" pm="."><plain>Gene expression data are available in the NCBI Gene Expression Omnibus (GEO) (Accession number GSE36335). </plain></SENT>
<SENT sid="104" pm="."><plain>Biological pathways were identified using the web-based DAVID software with a FDR ≤5% [25]. </plain></SENT>
</text></p></sec><sec id="s2e"><title><text><SENT sid="105" pm="."><plain>Real Time Quantitative Reverse Transcription PCR (qRT-PCR) </plain></SENT>
</text></title><p><text><SENT sid="106" pm="."><plain>qRT-PCR was used to technically validate increased/decreased expression of 5 cancer-related genes with differential expression between the 4 colorectal cancer subsets. </plain></SENT>
<SENT sid="107" pm="."><plain>The genes were selected to represent major deregulated pathways and expression levels were investigated in 3 samples from each subtype. </plain></SENT>
<SENT sid="108" pm="."><plain>The rRNA18S was used as internal reference gene and normal colon sample as a calibrator. </plain></SENT>
<SENT sid="109" pm="."><plain>Gene-specific primers and taqman probe sets for each gene were obtained from Applied Biosystems (Applied Biosystems, Foster City, CA). </plain></SENT>
<SENT sid="110" pm="."><plain>Reverse transcription and PCR was performed using Quantitect reverse transcription kit and probe PCR kit, respectively (Qiagen, Heidelberg, Germany). </plain></SENT>
</text></p></sec><sec id="s2f"><title><text><SENT sid="111" pm="."><plain>Validation in External Data </plain></SENT>
</text></title><p><text><SENT sid="112" pm="."><plain>The hereditary gene expression signature was validated using the GSE4554 data set and the four largest batches of The Cancer Genome Atlas Network (TCGA) RNAseqv2 [26], [27]. </plain></SENT>
<SENT sid="113" pm="."><plain>In order to resemble microarray data, the RPKM values of the TCGA were quantile-normalized, an offset of 32 was added, capped at 65,000, and genes were centered. </plain></SENT>
<SENT sid="114" pm="."><plain>Subsequently the data was adjusted for the batch variable. </plain></SENT>
<SENT sid="115" pm="."><plain>All data were imported into MeV v4, log2 transformed, genes were median-centered across assays and the 50% least-varying genes were removed. </plain></SENT>
<SENT sid="116" pm="."><plain>Unsupervised hierarchical clustering was performed as described above. </plain></SENT>
<SENT sid="117" pm="."><plain>A gene expression centroid was constructed by averaging the expression values of the samples in Lynch syndrome and FCCTX for each gene in order to establish a signature classifier for nearest centroid classification. </plain></SENT>
<SENT sid="118" pm="."><plain>A sample from the external datasets was assigned to either of the two hereditary subsets based on the maximum Pearson correlation of its centroid expression to the hereditary centroid values. </plain></SENT>
</text></p></sec><sec id="s2g"><title><text><SENT sid="119" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="120" pm="."><plain>Clinical association (tumor location, differentiation, age at onset and stage) in Lynch syndrome and FCCTX were determined using the Fisher’s exact test (with significance set for P&lt;0.05). </plain></SENT>
<SENT sid="121" pm="."><plain>The statistical analyses were performed using the statistical software package IBM SPSS Statistics 20 (SPSS, Chicago, IL, USA). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="s3"><title><text><SENT sid="122" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="123" pm="."><plain>Unsupervised hierarchical clustering analysis in the whole series (including 39 Lynch syndrome tumors, 37 FCCTX tumors, 21 sporadic MMR proficient tumors and 26 sporadic MMR deficient tumors) identified two major subgroups related to MMR status (Figure S1). </plain></SENT>
<SENT sid="124" pm="."><plain>The intrinsic MMR signature was strong with 3873 differentially expressed genes, of which 2159 (56%) were up-regulated in the MMR defective tumors and were related to 5 signaling pathways (Table S1). </plain></SENT>
</text></p><p><text><SENT sid="125" pm="."><plain>In the hereditary tumor subset, SAM analysis identified 2188 differentially expressed genes between FCCTX and Lynch syndrome tumors (Figure 1). </plain></SENT>
<SENT sid="126" pm="."><plain>In FCCTX tumors, the G-protein coupled signaling pathway was up-regulated (FDR = 0.6%), whereas Lynch syndrome tumors showed up-regulation of 2 pathways related to cell cycle and mitosis (FDR = 1.4%) and oxidative phosphorylation (FDR = 3.5%) (Table 2). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0071755-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071755.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="127" pm="."><plain>Clustering based on differentially expressed genes between FCCTX and Lynch syndrome tumors, identified by SAM analysis. </plain></SENT>
</text></title><p><text><SENT sid="128" pm="."><plain>The figure depicts the top-360 differentially expressed genes. </plain></SENT>
<SENT sid="129" pm="."><plain>Samples are arranged along the x-axis and show FCCTX tumors (green) and Lynch syndrome tumors (blue). </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0071755.g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone-0071755-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071755.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="130" pm="."><plain>Up-regulated signaling pathways in FCCTX and Lynch syndrome tumors. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0071755-t002-2" xlink:href="pone.0071755.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>Tumor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>Pathway </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>P-value </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>FDR (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>Genes </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>FCCTX </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>Signaling by G-protein coupled receptor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>5×10−4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>0.589 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>GNAS, F2R, F2RL2, EDN1, EDNRA, GRM8, GNAZ, GNG11, GNG12, HCRT, PTGER1, P2RY2, RAMP2, MC1R, TUBB3, VIP </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>Tumor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>Pathway </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>P-value </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>FDR (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>Genes </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>Lynch syndrome </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>Cell cycle and mitosis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>0.001 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>1.416 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>CDC45, DNA2, E2F2, MIS12, MLF1IP, WEE1, ZWILCH, ANAPC4, ANAPC5, BUB3, CASC5, CDC20, CENPM, CEP135, CCNB2, CCNE1, CCNH, CDK2, CDKN1A, DHFR, FEN1, HSP90AA1, HSP90AA2, KIF2C, KNTC1, MCM4, NUP37, PCNT, PCM1, PTTG1, PTTG2, PLK4, POLE, POLD3, PSMD2, PSMD5, PSME1, PSME2, PSMA4, PSMA5, PSMA6, PSMB2, PSMB4, PSMB6, PPP1CC, PPP2CB, PPP2R5B, RFC5, RPA1, RRM2, STAG1, TYMS, LOC442308, TUBB, TUBBP1, TUBBP2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>Oxidative phosphorylation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>0.003 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>3.508 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>ATP5L, ATP5A1, ATP5B, ATP5D, ATP6V1B2, ATP6V1A, NDUFA7, NDUFA8, NDUFA9, NDUFB2, NDUFAB1, NDUFS2, NDUFV2, TCIRG1, COX7B, COX7C, COX6A1, COX5A, PPA2, LOC100130320, SDHD, SDHA, UQCR10, UQCRFS1, UQCRFSL1, UQCRQ </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><p><text><SENT sid="155" pm="."><plain>The gene expression profiles of FCCTX tumors were closely related to those in sporadic MMR proficient colorectal cancers with genes involved in peptidyl-amino acid modification, enzyme linked receptor protein signaling and growth regulation. </plain></SENT>
<SENT sid="156" pm="."><plain>Likewise, Lynch syndrome and sporadic MMR defective tumors shared genes involved in cell cycle progression and immune response. </plain></SENT>
<SENT sid="157" pm="."><plain>Comparison between FCCTX and sporadic MMR proficient tumors revealed 4 differentially expressed genes, whereas comparison between FCCTX and sporadic MMR deficient tumors identified 3906 differentially expressed genes. </plain></SENT>
<SENT sid="158" pm="."><plain>Lynch syndrome tumors differed from sporadic MMR stable tumors by 415 differentially expressed genes and from sporadic MMR deficient tumors by 91 genes. </plain></SENT>
<SENT sid="159" pm="."><plain>Among sporadic tumors, 1384 genes differed MMR proficient and deficient tumors. </plain></SENT>
</text></p><p><text><SENT sid="160" pm="."><plain>The genetic profiles were validated in independent datasets, i.e. the GSE4554 (Affymetrix microarray) and the TCGA (RNA sequencing) [26], [27]. </plain></SENT>
<SENT sid="161" pm="."><plain>Both datasets mainly comprise sporadic colorectal cases, including 51 MMR stable tumors and 33 MMR defective tumors in the GSE4554 data set and 91 MMR stable, 19 MMR defective and 28 MMR-low stable tumors in the TCGA data set. </plain></SENT>
<SENT sid="162" pm="."><plain>Unsupervised hierarchical clustering based on our 2188 gene signature identified by us, resulted in two major groups related to MMR status. </plain></SENT>
<SENT sid="163" pm="."><plain>The hereditary signature correctly classified 82% and 80% of the MMR stable tumors as FCCTX and 100% and 94% of the MMR defective tumors as Lynch syndrome, respectively (Figure 2). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0071755-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071755.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="164" pm="."><plain>Unsupervised hierarchical clustering based on our 2188-gene signature applied to external data sets. </plain></SENT>
</text></title><p><text><SENT sid="165" pm="."><plain>a) Clustering based on GSE4554 and b) Clustering based on the four largest batches of the TCGA RNAseqv2 data sets. </plain></SENT>
<SENT sid="166" pm="."><plain>MMR proficient tumors (green), microsatellite-low tumors (blue) and MMR deficient tumors (red) along the x-axis. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0071755.g002"/></fig></SecTag><p><text><SENT sid="167" pm="."><plain>qRT-PCR-based technical validation was performed using 5 cancer-related genes representing deregulated pathways observed in MMR stable and deficient tumors, respectively (Figure 3). </plain></SENT>
<SENT sid="168" pm="."><plain>The results confirmed increased expression of MYC and AXIN2 in FCCTX tumors, decreased expression of NDUFA9 in FCCTX tumors and in sporadic MMR proficient tumors and increased expression of H2AFZ in MMR deficient tumors. </plain></SENT>
<SENT sid="169" pm="."><plain>No major differences were observed for DNA2. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0071755-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071755.g003</object-id><label>Figure 3</label><caption><title><text><SENT sid="170" pm="."><plain>qRT-PCR analysis of 5 target genes in the four different colorectal cancer subsets. </plain></SENT>
</text></title><p><text><SENT sid="171" pm="."><plain>Differential expression of MYC, NDUFA9, H2AFZ, AXIN2, and DNA2 was done for 12 representative samples (3 from each group) and qRT-PCR ratios were normalized to rRNA18S and median centered. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0071755.g003"/></fig></SecTag></sec></SecTag><SecTag type="DISCUSS"><sec id="s4"><title><text><SENT sid="172" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="173" pm="."><plain>Within the HNPCC subset of hereditary colorectal cancer, we demonstrated distinctively different gene expression signatures in FCCTX and Lynch syndrome tumors, which differ by 2188 genes. </plain></SENT>
<SENT sid="174" pm="."><plain>Based on these gene expression differences, our data suggest that MMR status strongly influences genetic signatures, also within phenotypically similar families, which is in agreement to previous studies on sporadic colorectal cancer [16]–[18], [27], [36]. </plain></SENT>
<SENT sid="175" pm="."><plain>The FCCTX and Lynch syndrome profiles differed in 3 major cancer-related pathways, primarily related to cell cycle progression andmitosis, oxidative phosphorylation and G protein coupled receptor signaling, which have been correlated to colorectal carcinogenesis [18], [28], [29], [36]. </plain></SENT>
</text></p><p><text><SENT sid="176" pm="."><plain>The FCCTX tumors showed up-regulation of 1059 genes, several (n = 16) of which were related to the G-protein coupled receptor pathway (Table 2). </plain></SENT>
<SENT sid="177" pm="."><plain>A candidate target herein includes the GNAS gene, which encodes for the Gα-subunit, and is located in the 20q13.32 region that has been found to be gained in FCCTX tumors [9], [12], [13]. </plain></SENT>
<SENT sid="178" pm="."><plain>Activating mutations in GNAS have been described in CRC and are suggested to promote tumorigenesis through activation of the Wnt and ERK1/2 MAPK signaling pathways [28], [29]. </plain></SENT>
<SENT sid="179" pm="."><plain>The potential tumorigenic mechanism is unknown and the hot-spot mutation GNAS c.601G&gt;T has not been observed in FCCTX tumors [12]. </plain></SENT>
<SENT sid="180" pm="."><plain>Also other candidate genes involved in proliferation and migration, e.g. CDH26, SRC and ASIP are located in 20q [30], [31]. </plain></SENT>
<SENT sid="181" pm="."><plain>The FCCTX tumors also showed up-regulation of PTGER1, which encodes for the EP1 receptor that may promote proliferation and colorectal tumor development through altered function of prostaglandin E2 (PGE2) [32]–[34]. </plain></SENT>
</text></p><p><text><SENT sid="182" pm="."><plain>Lynch syndrome tumors showed up-regulation of 1129 genes, e.g. genes involved in G1/S transition (CCNE, CCNH, E2F2 and CDK2), DNA replication (CDC45, RPA1, RFC5, MCM4 and POLD3) and chromosomal organization and mitosis (CCNB2, MLF1IP, CASC5, KIF2C and PLK4), which is in line with previous findings (Table 2) [16], [18], [35], [36]. </plain></SENT>
<SENT sid="183" pm="."><plain>Up-regulation of e.g. WEE1, CDKN1A and FANCD2 were also observed in our study and have also been reported by other investigators, which may suggest involvement of the cell cycle checkpoint machinery [37], [38]. </plain></SENT>
<SENT sid="184" pm="."><plain>Overexpression of checkpoint proteins have previously been linked to Lynch syndrome and abrogation of the checkpoint machinery has been shown to sensitize MMR deficient tumor cells towards chemotherapy [39], [40]. </plain></SENT>
<SENT sid="185" pm="."><plain>Also genes involved in the oxidative phosphorylation pathway, e.g. the ATP synthase subunit genes and complex I and III subunit genes were among those up-regulated in Lynch syndrome tumors. </plain></SENT>
<SENT sid="186" pm="."><plain>Down-regulation of ATP synthase subnit genes and complex I, III and V genes have been correlated to metastastic colorectal cancer and may explain the more aggressive tumor development and poor prognosis observed in MMR proficient tumors [11], [18], [41]. </plain></SENT>
</text></p><p><text><SENT sid="187" pm="."><plain>In colorectal cancer, MMR status is a major discriminator related to distinctively different gene expression profiles, which is supported by the 3873 differentially expressed genes in our series of MMR deficient and proficient tumors [15], [16], [27]. </plain></SENT>
<SENT sid="188" pm="."><plain>The importance of MMR status was observed also when we applied the 2188-gene signature that discriminated between Lynch syndrome and FCCTX to two independent data sets mainly containing sporadic tumors. </plain></SENT>
<SENT sid="189" pm="."><plain>The signature correctly defined 80–82% of the MMR proficient and 94–100% of MMR deficient tumors (Figure 2). </plain></SENT>
<SENT sid="190" pm="."><plain>Several heat shock proteins and immune response genes (Table S1) were up-regulated in the MMR defective tumors, which supports involvement of immune-response mechanisms, irrespective of whether the tumor was caused by germline or somatic MMR gene inactivation [16]–[18], [42], [43]. </plain></SENT>
<SENT sid="191" pm="."><plain>In sporadic as well as hereditary MMR proficient tumors several genes in the Wnt signaling were up-regulated, which fits well with its central role in colorectal tumorigenesis (Table S1) [44], [45]. </plain></SENT>
</text></p><p><text><SENT sid="192" pm="."><plain>In conclusion, hereditary colorectal cancers within the HNPCC subset show distict genetic profiles with 2188 differentially expressed genes between Lynch syndrome and FCCTX. </plain></SENT>
<SENT sid="193" pm="."><plain>These data pinpoint genes and pathways relevant to further pursue for refined diagnostics and therapeutics in hereditary colorectal cancer. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s5"><title><text><SENT sid="194" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0071755.s001"><label>Figure S1</label><caption><p><text><SENT sid="195" pm="."><plain>Unsupervised hierarchical clustering of the entire dataset. The dendogram shows the spontaneous clustering of 123 colorectal cancers into two major clusters related to MMR status. </plain></SENT>
<SENT sid="196" pm="."><plain>MMR proficient tumors (green), including FCCTX tumors and sporadic MMR proficient tumors and MMR deficient tumors (blue), including Lynch syndrome tumors and sporadic MMR deficient tumors. </plain></SENT>
</text></p><p><text><SENT sid="197" pm="."><plain>(TIF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0071755.s001.tif"><caption><p><text><SENT sid="198" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0071755.s002"><label>Table S1</label><caption><p><text><SENT sid="199" pm="."><plain>Signaling pathways up-regulated in MMR proficient and MMR deficient tumors. </plain></SENT>
</text></p><p><text><SENT sid="200" pm="."><plain>(XLS) </plain></SENT>
</text></p></caption><media xlink:href="pone.0071755.s002.xls"><caption><p><text><SENT sid="201" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="202" pm="."><plain>We thank Eva Rambech and Martin Lauss, Department of Oncology, Institute of Clinical Sciences, Lund University and Anja Nissen, Clinical Research Centre, Copenhagen University Hospital, Hvidovre for technical help and assistance and Sabrina Da Silva, Department of Medicine and Oncology, Sir Mortimer B, Davis-Jewish General Hospital, McGill University, Montreal, Canada for statistical support. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0071755-Mecklin1"><text><SENT sid="203" pm="."><plain>1Mecklin JP, Järvinen HJ (2005) Surveillance in Lynch syndrome. </plain></SENT>
<SENT sid="204" pm="."><plain>Fam Cancer 4: 267–271. </plain></SENT>
<SENT sid="205" pm="."><plain>Review. </plain></SENT>
</text></ref><ref id="pone.0071755-Balmaa1"><text><SENT sid="206" pm="."><plain>2 BalmañaJ, CastellsA, CervantesA (2010) ESMO Guidelines Working Group (2010) Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. Ann Oncol 5: v78–81. </plain></SENT>
</text></ref><ref id="pone.0071755-Vasen1"><text><SENT sid="207" pm="."><plain>3 VasenHF, MecklinJP, KhanPM, LynchHT (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34: 424–425.2022152 </plain></SENT>
</text></ref><ref id="pone.0071755-Vasen2"><text><SENT sid="208" pm="."><plain>4 VasenHF, WatsonP, MecklinJP, LynchHT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116: 1453–1456.10348829 </plain></SENT>
</text></ref><ref id="pone.0071755-Lynch1"><text><SENT sid="209" pm="."><plain>5 LynchHT, LynchPM (2005) Molecular screening for the Lynch syndrome–better than family history? N Engl J Med 352: 1920–1922.15872208 </plain></SENT>
</text></ref><ref id="pone.0071755-Jass1"><text><SENT sid="210" pm="."><plain>6Jass JR (2006) Colorectal cancer: a multipathway disease. </plain></SENT>
<SENT sid="211" pm="."><plain>Crit Rev Oncog 12: 273–287. </plain></SENT>
<SENT sid="212" pm="."><plain>Review. </plain></SENT>
</text></ref><ref id="pone.0071755-Vasen3"><text><SENT sid="213" pm="."><plain>7 VasenHF, MösleinG, AlonsoA, BernsteinI, BertarioL, et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44: 353–362.17327285 </plain></SENT>
</text></ref><ref id="pone.0071755-Lindor1"><text><SENT sid="214" pm="."><plain>8 LindorNM, RabeK, PetersenGM, HaileR, CaseyG, et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. </plain></SENT>
<SENT sid="215" pm="."><plain>JAMA. 293: 1979–1985. </plain></SENT>
</text></ref><ref id="pone.0071755-AbdelRahman1"><text><SENT sid="216" pm="."><plain>9 Abdel-RahmanWM, OllikainenM, KariolaR, JärvinenHJ, MecklinJ, et al (2005) Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene 24: 1542–1551.15674332 </plain></SENT>
</text></ref><ref id="pone.0071755-Llor1"><text><SENT sid="217" pm="."><plain>10 LlorX, PonsE, XicolaRM, CastellsA, AlendaC, et al (2005) Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res 11: 7304–7310.16243801 </plain></SENT>
</text></ref><ref id="pone.0071755-Klarskov1"><text><SENT sid="218" pm="."><plain>11 KlarskovL, HolckS, BernsteinI, NilbertM (2012) Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome. J Clin Pathol 65: 352–356.22287689 </plain></SENT>
</text></ref><ref id="pone.0071755-Middeldorp1"><text><SENT sid="219" pm="."><plain>12 MiddeldorpA, Van EijkR, OostingJ, ForteGI, van PuijenbroekM, et al (2012) Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. Int J Cancer 130: 837–846.21445971 </plain></SENT>
</text></ref><ref id="pone.0071755-Therkildsen1"><text><SENT sid="220" pm="."><plain>13Therkildsen C, Jönsson G, Dominguez-Valentin M, Nissen A, Rambech E, et al.. </plain></SENT>
<SENT sid="221" pm="."><plain>(2012) Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer. </plain></SENT>
<SENT sid="222" pm="."><plain>Eur J Cancer. </plain></SENT>
<SENT sid="223" pm="."><plain>Dec 11. doi:pii: S0959–8049(12)00896–9.10.1016/j.ejca.2012.11.011. </plain></SENT>
</text></ref><ref id="pone.0071755-Lee1"><text><SENT sid="224" pm="."><plain>14 LeeWS, SeoG, ShinHJ, YunSH, YunH, et al (2008) Identification of differentially expressed genes in microsatellite stable HNPCC and sporadic colon cancer. J Surg Res 144: 29–35.17950328 </plain></SENT>
</text></ref><ref id="pone.0071755-SnchezdeAbajo1"><text><SENT sid="225" pm="."><plain>15 Sánchez-de-AbajoA, de la HoyaM, van PuijenbroekM, TosarA, López-AsenjoJA, et al (2007) Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. Clin Cancer Res 13: 5729–5735.17908962 </plain></SENT>
</text></ref><ref id="pone.0071755-Kim1"><text><SENT sid="226" pm="."><plain>16 KimH, NamSW, RheeH, Shan LiL, Ju KangH, et al (2004) Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. Oncogene 23: 6218–6225.15208663 </plain></SENT>
</text></ref><ref id="pone.0071755-Banerjea1"><text><SENT sid="227" pm="."><plain>17 BanerjeaA, AhmedS, HandsRE, HuangF, HanX, et al (2004) Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 3: 21.15298707 </plain></SENT>
</text></ref><ref id="pone.0071755-Bertucci1"><text><SENT sid="228" pm="."><plain>18 BertucciF, SalasS, EysteriesS, NasserV, FinettiP, et al (2004) Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23: 1377–1391.14973550 </plain></SENT>
</text></ref><ref id="pone.0071755-Fan1"><text><SENT sid="229" pm="."><plain>19 FanJB, YeakleyJM, BibikovaM, ChudinE, WickhamE, et al (2004) A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14: 878–885.15123585 </plain></SENT>
</text></ref><ref id="pone.0071755-Kuhn1"><text><SENT sid="230" pm="."><plain>20 KuhnK, BakerSC, ChudinE, LieuMH, OeserS, et al (2004) A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res 14: 2347–2356.15520296 </plain></SENT>
</text></ref><ref id="pone.0071755-Workman1"><text><SENT sid="231" pm="."><plain>21 WorkmanC, JensenLJ, JarmerH, BerkaR, GautierL, et al (2002) A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 30 3(9): research0048. </plain></SENT>
</text></ref><ref id="pone.0071755-Saeed1"><text><SENT sid="232" pm="."><plain>22 SaeedAI, SharovV, WhiteJ, LiJ, LiangW, et al (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374–378.12613259 </plain></SENT>
</text></ref><ref id="pone.0071755-Tusher1"><text><SENT sid="233" pm="."><plain>23 TusherVG, TibshiraniR, ChuG (2001) Significance analysis of microarrays applied to the ionizing radiation response. </plain></SENT>
<SENT sid="234" pm="."><plain>Proc Natl Acad Sci USA 24: 5116–5121. Erratum in: Proc Natl Acad Sci USA 28: 10515. </plain></SENT>
</text></ref><ref id="pone.0071755-Benjamini1"><text><SENT sid="235" pm="."><plain>24 BenjaminiY, DraiD, ElmerG, KafkafiN, GolaniI (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279–284.11682119 </plain></SENT>
</text></ref><ref id="pone.0071755-Huangda1"><text><SENT sid="236" pm="."><plain>25 Huang daW, ShermanBT, LempickiRA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.19131956 </plain></SENT>
</text></ref><ref id="pone.0071755-CancerGenomeAtlas1"><text><SENT sid="237" pm="."><plain>26 Cancer Genome AtlasNetwork (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330–337.22810696 </plain></SENT>
</text></ref><ref id="pone.0071755-Watanabe1"><text><SENT sid="238" pm="."><plain>27 WatanabeT, KobunaiT, TodaE, YamamotoY, KanazawaT, et al (2006) Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res 66: 9804–988.17047040 </plain></SENT>
</text></ref><ref id="pone.0071755-Sjblom1"><text><SENT sid="239" pm="."><plain>28 SjöblomT, JonesS, WoodLD, ParsonsDW, LinJ, et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.16959974 </plain></SENT>
</text></ref><ref id="pone.0071755-Wilson1"><text><SENT sid="240" pm="."><plain>29 WilsonCH, McIntyreRE, ArendsMJ, AdamsDJ (2010) The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 29: 4567–4575.20531296 </plain></SENT>
</text></ref><ref id="pone.0071755-Hu1"><text><SENT sid="241" pm="."><plain>30 HuY, FangC, XuY (2005) The effect of isoforms of the cell polarity protein, human ASIP, on the cell cycle and Fas/FasL-mediated apoptosis in human hepatoma cells. Cell Mol Life Sci 62: 1974–1983.16091846 </plain></SENT>
</text></ref><ref id="pone.0071755-Jin1"><text><SENT sid="242" pm="."><plain>31 JinYT, YingXX, HuYH, ZouQ, WangHY, et al (2008) aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa-overexpressed breast cancer. Oncol Res 17 59–68.18543607 </plain></SENT>
</text></ref><ref id="pone.0071755-Watanabe2"><text><SENT sid="243" pm="."><plain>32 WatanabeK, KawamoriT, NakatsugiS, OhtaT, OhuchidaS, et al (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093–5096.10537280 </plain></SENT>
</text></ref><ref id="pone.0071755-Kim2"><text><SENT sid="244" pm="."><plain>33 KimSH, ParkYY, KimSW, LeeJS, WangD, et al (2011) ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res 71: 7010–7020.21937683 </plain></SENT>
</text></ref><ref id="pone.0071755-Greenhough1"><text><SENT sid="245" pm="."><plain>34Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, et al.. </plain></SENT>
<SENT sid="246" pm="."><plain>(2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. </plain></SENT>
<SENT sid="247" pm="."><plain>Carcinogenesis 30: 377–386. </plain></SENT>
<SENT sid="248" pm="."><plain>Review. </plain></SENT>
</text></ref><ref id="pone.0071755-Yuan1"><text><SENT sid="249" pm="."><plain>35 YuanZ, SotskyKT, WeberTK (2003) Differential expression of DOC-1 in microsatellite-unstable human colorectal cancer. Oncogene 22: 6304–6310.13679870 </plain></SENT>
</text></ref><ref id="pone.0071755-Dunican1"><text><SENT sid="250" pm="."><plain>36Dunican DS, McWilliam P, Tighe O, Parle-McDermott A, Croke DT (2002) Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density hybridization. </plain></SENT>
<SENT sid="251" pm="."><plain>Oncogene 21,3253–3257. </plain></SENT>
</text></ref><ref id="pone.0071755-Sinicrope1"><text><SENT sid="252" pm="."><plain>37 SinicropeFA, RoddeyG, LemoineM, RuanS, StephensLC, et al (1998) Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. Clin Cancer Res 4: 1251–1261.9607584 </plain></SENT>
</text></ref><ref id="pone.0071755-Duldulao1"><text><SENT sid="253" pm="."><plain>38 DuldulaoMP, LeeW, LeM, ChenZ, LiW, et al (2012) Gene expression variations in microsatellite stable and unstable colon cancer cells. J Surg Res 174: 1–6.21816436 </plain></SENT>
</text></ref><ref id="pone.0071755-Jardim1"><text><SENT sid="254" pm="."><plain>39 JardimMJ, WangQ, FurumaiR, WakemanT, GoodmanBK, WangXF (2009b) Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. Mol Biol Cell 20: 3801–3809.19570909 </plain></SENT>
</text></ref><ref id="pone.0071755-Pires1"><text><SENT sid="255" pm="."><plain>40 PiresIM, WardTH, DiveC (2010) Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. Br J Pharmacol 159: 1326–1338.20128802 </plain></SENT>
</text></ref><ref id="pone.0071755-Benatti1"><text><SENT sid="256" pm="."><plain>41 BenattiP, RoncucciL, GanazziD, PercesepeA, DiGC, et al (2001) Clinical and biologic heterogeneity of hereditary nonpolyposis colorectal cancer. Int J Cancer 95: 323–328.11494233 </plain></SENT>
</text></ref><ref id="pone.0071755-Belt1"><text><SENT sid="257" pm="."><plain>42 BeltEJ, BrosensRP, Delis-van DiemenPM, BrilH, TijssenM, et al (2012) Cell Cycle Proteins Predict Recurrence in Stage II and III Colon Cancer. Ann Surg Oncol 3: S682–692. </plain></SENT>
</text></ref><ref id="pone.0071755-Ogino1"><text><SENT sid="258" pm="."><plain>43 OginoS, NoshoK, IraharaN, MeyerhardtJA, BabaY, et al (2009) Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpGisland and methylator phenotype. Clin Cancer Res 15: 6412–6420.19825961 </plain></SENT>
</text></ref><ref id="pone.0071755-Yang1"><text><SENT sid="259" pm="."><plain>44 YangM, ZhongWW, SrivastavaN, SlavinA, YangJ, et al (2005) G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci USA 102: 6027–6032.15837931 </plain></SENT>
</text></ref><ref id="pone.0071755-Malbon1"><text><SENT sid="260" pm="."><plain>45Malbon CC (2005). </plain></SENT>
<SENT sid="261" pm="."><plain>Beta-catenin, cancer, and G proteins: not just for frizzleds anymore. </plain></SENT>
<SENT sid="262" pm="."><plain>Sci STKE 292: pe35. </plain></SENT>
<SENT sid="263" pm="."><plain>Review. </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
